Serum FST levels was found higher in lung cancer patients respect to healthy subjects and in patients with lung benign disease [61], while TEAD2 targeting was responsible of cisplatin sensitization in NSCLC [62]. This evidence concerns the gene TEAD2 and lung cancer.